Joachim W.
- Country
- Germany
- Department
- Hausärztliche Gemeinschaftspraxis
Research Overview
- Efficacy, Safety, and Immunogenicity of mRNA-1647 Vaccine in Preventing Primary Cytomegalovirus Infection in CMV-Seronegative Females Aged 16-40
- Efficacy and Safety of MET097 in Adults with Overweight or Obesity: A Phase 3, Randomized, Placebo-Controlled Trial
- Phase 3 Randomized, Placebo‑Controlled Trial Assessing Efficacy and Safety of MET097, a Long‑Acting GLP‑1 Receptor Agonist, in Overweight/Obese Adults with Type 2 Diabetes
Data & Insights
Has run more than one trial at 694 of 1483 partner sites.
Specializations
Cardiovascular disease and cardiometabolic risk
Joachim Weimer is involved in clinical research focused on atherosclerotic cardiovascular disease, heart failure prevention, and broader cardiovascular risk reduction, with attention to patients carrying multiple metabolic risk factors.
- Major adverse cardiovascular events
- Lipoprotein(a)-related risk
- Hypertension with established cardiovascular disease
- Obesity and overweight
His trial portfolio also includes therapeutic interest in lipid management and integrated treatment strategies for patients with combined cardiovascular and metabolic disease.
Chronic pain and musculoskeletal disorders
His research landscape includes treatment areas for chronic pain syndromes, especially pain linked to diabetic peripheral neuropathy, knee osteoarthritis, and chronic non-specific low back pain.
- Neuropathic pain
- Osteoarthritis-related pain
- Low back pain
- Non-opioid pain treatment
He is also active in studies addressing symptom control where conventional analgesic approaches have not provided sufficient relief.
Kidney disease and blood pressure disorders
Joachim Weimer participates in research on chronic kidney disease associated with hypertension, including therapeutic approaches aimed at slowing renal decline and improving blood pressure control.
- Renal protection
- RAAS regulation
- Primary aldosteronism
- Cardiorenal disease
His involvement extends to conditions where kidney and cardiovascular complications overlap, reflecting a clear focus on cardiorenal therapeutics.
Metabolic disease and weight management
His clinical trial activity includes type 2 diabetes mellitus and obesity, with emphasis on therapies that influence glycaemic control, body weight, and cardiovascular outcomes in high-risk populations.
- Type 2 diabetes
- Weight reduction
- Metabolic-cardiovascular overlap
- Risk-factor modification
He is also engaged in research that connects metabolic treatment with prevention of downstream cardiovascular and renal complications.
Infectious disease and symptom-focused therapy
Joachim Weimer also contributes to studies in infectious disease prevention and symptomatic treatment, including work on cytomegalovirus infection, invasive Escherichia coli disease, and acute pharyngitis.
- Vaccination against CMV
- Bacterial infection prevention
- Upper respiratory tract symptom relief
- Irritable bowel syndrome
His portfolio also includes gastrointestinal symptom management in irritable bowel syndrome, broadening his therapeutic focus beyond cardiometabolic care.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.